HIGHLIGHTS OF PRESCRIBING INFORMATION 

These highlights do not include all the information needed to use LuciAnagre safely and effectively. See full prescribing information for LuciAnagre.

INDICATIONS AND USAGE

Anagrelide is a platelet reducing agent indicated for the treatment of thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. 

DOSAGE AND ADMINISTRATION 

 The starting dose for adults is 0.5 mg four times a day or 1 mg twice a day.

 The starting dose for pediatric patients is 0.5 mg per day.

 Maintain the starting dose for at least one week and then titrate to maintain target platelet counts.  Do not exceed a dose increment of 0.5 mg/day in any one week. Do not exceed 10 mg/day or 2.5 mg in a single dose. 

 Moderate hepatic impairment: Start with 0.5 mg per day.

DOSAGE FORMS AND STRENGTHS 

Tablets: 0.5 mg×100 capsules

CONTRAINDICATIONS 

None.

WARNINGS AND PRECAUTIONS 

 Cardiovascular Toxicity: QT prolongation and ventricular tachycardia have been reported with anagrelide. Obtain a pre-treatment cardiovascular examination including an ECG in all patients. Monitor patients for cardiovascular effects. 

 Pulmonary Hypertension: Assess underlying cardiopulmonary disease prior to initiating therapy. 

 Bleeding Risk: Monitor patients for bleeding, including those receiving concomitant therapy with other drugs known to cause bleeding.

ADVERSE REACTIONS 

The most common adverse reactions (incidence ≥ 5%) are headache, palpitations, diarrhea, asthenia, edema, nausea, abdominal pain, dizziness, pain, dyspnea, cough, flatulence, vomiting, fever, peripheral edema, rash, chest pain, anorexia, tachycardia, malaise, paresthesia, back pain, pruritus, dyspepsia.

DRUG INTERACTIONS 

 Other PDE 3 inhibitors: Exacerbation of inotropic effects.

 Aspirin and Drugs that Increase Bleeding Risk: Increased risk of bleeding with concomitant use.

USE IN SPECIFIC POPULATIONS 

 Nursing Mothers: Discontinue nursing or discontinue the drug .

Storage 

Store at 20℃ to 25℃ (68℉ to 77℉), excursions permitted between 15℃ and 30℃ (59℉ and 86℉) [see USP Controlled Room Temperature]. Protect from moisture.